Immunomedics of Morris Plains, NJ, said last month that the EuropeanPatent Office has issued a decision maintaining its patent forusing antibodies for carcinoembryonic antigen (CEA) that are effectivefor targeting tumors with imaging and therapy agents.
Immunomedics of Morris Plains, NJ, said last month that the EuropeanPatent Office has issued a decision maintaining its patent forusing antibodies for carcinoembryonic antigen (CEA) that are effectivefor targeting tumors with imaging and therapy agents. The patenthad been challenged by Behringwerke AG of Germany, which did notappeal the patent office's decision denying its request, accordingto Immunomedics. The company's stock jumped 24% after the patentnews was announced.
CMS Issues New Reimbursement Code for PSMA PET Agent POSLUMA
September 26th 2023The transitional pass-through payment reimbursement code for the FDA-approved PSMA PET agent for prostate cancer detection will be effective as of October 1, according to the Centers for Medicare and Medicare Services (CMS).
2 Clarke Drive
Cranbury, NJ 08512